Ryan Scott

Articles

Breast cancer | Image Credit: Crystal Light - stock.adobe.com

December 22nd 2023

Neoadjuvant KN026 Plus Docetaxel Demonstrate Early Activity in HER2+ Breast Cancer

A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.

Stomach cancer art | Image credit: Crystal light - stock.adobe.com

October 20th 2023

Frontline Pembrolizumab Plus Trastuzumab/Chemotherapy Improves PFS in HER2+ Gastric/GEJ Cancer

Ryan Scott

Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.

July 22nd 2022

ASCO Spotlight With David R. Penberthy, MD, MBA: Knowledge Gained at ASCO Can Transform Cancer Care

Maggie L. Shaw Ryan Scott

July 21st 2022

ASCO Spotlight With Thanos Zomas, MD: Hodgkin Lymphoma Outcomes Improve With Targeted Treatment

Maggie L. Shaw Ryan Scott

Thanos Zomas, MD, global medical lead for lymphoma and leukemia and for the Adcetris Program, Takeda Oncology, discussed results of the ECHELON-1 trial.